title: FDA gives salvage therapy testing a push forward.
abstract: Pharmaceutical companies like to test their drugs in  patients who are less seriously ill, so that the drugs will look good. A recent FDA meeting focused attention on the need for more trials in advanced patients, the importance of long-term safety follow-up for all patients, and how the necessary trials and monitoring could be conducted.
authors.forename: E
authors.initials: E
authors.lastname: Bass
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D016879:Salvage Therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral